Advertisment

Sanofi to Release 230,000 Additional Doses of RSV Immunization Nirsevimab: What It Means for Public Health

author-image
Medriva Correspondents
New Update
Sanofi to Release 230,000 Additional Doses of RSV Immunization Nirsevimab: What It Means for Public Health

Sanofi to Release 230,000 Additional Doses of RSV Immunization Nirsevimab: What It Means for Public Health

Advertisment

Respiratory syncytial virus (RSV) is a common respiratory virus that primarily affects infants and older adults. It's a major cause of respiratory illness and, in severe cases, can lead to hospitalization or even death. The development and effective distribution of immunization against this virus is therefore an essential step in public health. This is where the RSV immunization nirsevimab comes into play.

Advertisment

Pharmaceutical giants Sanofi and AstraZeneca have taken a significant step to address the increasing demand for RSV immunization. They have announced the release of an additional 230,000 doses of the RSV immunization nirsevimab in January 2024. This announcement brings hope for better protection against the virus, especially for high-risk populations such as infants and older adults.

Understanding Nirsevimab

Nirsevimab, also known as Beyfortus, is a long-acting monoclonal antibody that induces immunity against RSV. It does this by targeting and binding to the part of the virus that it uses to attach to host cells. This mechanism of action allows Beyfortus to prevent infection at a cellular level, leading to passive immunity in infants.

Advertisment

Impact of the Additional Doses

The release of these additional doses is expected to have a positive impact on the prevention and management of RSV infections. The new supply deal will bring the first season to an immunization rate of nearly 40%, representing a total of 1.4 million babies being offered protection against RSV.

Addressing the Supply-Demand Gap

Advertisment

The demand for RSV immunization has been unprecedented, leading to supply problems. In response, Sanofi and AstraZeneca are taking proactive steps to boost their supply line for the coming RSV seasons. They are working with stakeholders to better assess demand and are augmenting their manufacturing network for Beyfortus. This is expected to ensure a steady supply of immunization, meeting the demand, and offering better protection to vulnerable populations.

New Developments in RSV Immunization

In addition to Beyfortus, there are other developments in RSV immunization. The FDA has approved Pfizer's new RSV vaccine called Abrysvo for use in pregnant women, and the CDC's vaccine advisory group has recommended that pregnant women between 32 to 36 weeks gestation receive the vaccine as a single intramuscular dose. These developments, along with the release of additional doses of Beyfortus, are promising steps toward better management and prevention of RSV infections.

Conclusion

In conclusion, the release of additional doses of the RSV immunization nirsevimab is a significant development in public health. It addresses the increasing demand for RSV immunization and offers hope for better protection against the virus. As Sanofi and AstraZeneca continue to boost their supply line and work with stakeholders, the future of RSV prevention looks promising.

Immunization Respiratory Syncytial Virus
Advertisment
Chat with Dr. Medriva !